Ph.D., Vice President, Molecular Diagnostics, Clovis Oncology
Dr. Raponi is responsible for designing and executing companion diagnostic strategies to support the development and commercialization of effective cancer therapeutics. Clovis Oncology currently has three compounds advancing in the clinic, each of which has a companion diagnostic also under development. These include CO-1686 (an EGFR mutant selective inhibitor) for the treatment of non-small cell lung cancer, rucaparib (an inhibitor of PARP) for the treatment of cancers with deficiencies in DNA repair, and lucitanib (an inhibitor of FGF and VEGF receptors) being developed in advanced breast and squamous cell lung cancer. He previously spent 15 years at Johnson & Johnson, building biomarker and companion diagnostic programs within the diagnostics (Veridex and Ortho-Clinical Diagnostics) and pharmaceutical (Janssen) franchises. Dr. Raponi received his Ph.D. in Molecular Genetics and Biochemistry from the University of New South Wales, Australia, and has published in the fields of gene therapy, cancer genomics and personalized medicine.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Successful translation of predictive biomarkers into the clinic is dependent on multiple aspects including a prospective outcomes analysis, a clear definition of the biomarker sensitivity and specificity requirements, and clinical trial design. Examples of impactful biomarkers in current clinical practice will be discussed.